Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
ILA-H82E5 | Human | Biotinylated Human IL-15 R alpha Protein, His,Avitag™ (MALS verified) |
|
||
ILA-HP2F6 | Human | PE-Labeled Human IL-15 R alpha / CD215 Protein, Fc Tag (Site-specific conjugation) | |||
ILA-HF255 | Human | FITC-Labeled Human IL-15 R alpha / CD215 Protein, Fc Tag (MALS verified) |
|
||
ILA-M5253 | Mouse | Mouse IL-15 R alpha / CD215 Protein, Fc Tag |
|
||
ILA-H82F4 | Human | Biotinylated Human IL-15 R alpha / CD215 Protein, Fc,Avitag™ (MALS verified) |
|
||
ILA-H5253 | Human | Human IL-15 R alpha / CD215 Protein, Fc Tag (MALS verified) |
|
Immobilized Human IL-15, His Tag (Cat. No. IL5-H52H8) at 2 μg/mL (100 μL/well) can bind FITC-Labeled Human IL-15 R alpha, Fc Tag (Cat. No. ILA-HF255) with a linear range of 0.078-5 μg/mL (QC tested).
The purity of Biotinylated Human IL-15 R alpha Protein, His,Avitag (Cat. No. ILA-H82E5) is more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
NKTR-255 | NKTR-255 | Phase 3 Clinical | Nektar Therapeutics | Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Multiple Myeloma; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
SHR-1501 | SHR-1501 | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd | Neoplasms; Urinary Bladder Neoplasms | Details |
XmAb24306 | XmAb-24306; RG-6323; RO-7310729; XmAb-306 | Phase 1 Clinical | Genentech Inc, Xencor Inc | Solid tumours; Neoplasms; Multiple Myeloma | Details |
BJ-001(Boji Biomedical Technology) | BJ-001 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Solid tumours; Communicable Diseases; Neoplasm Metastasis | Details |
ASKG-915 | ASKG-915 | Phase 1 Clinical | Askgene Pharma | Solid tumours; Neoplasms | Details |
ASKG-315 | ASKG-315; ASKG-215b; ASKG-215β | Phase 1 Clinical | Askgene Pharma | Solid tumours; Neoplasms | Details |
VG-201 | VG-201 | Phase 1 Clinical | ViroGin Biotech Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
VG-203 | VG-203; VG2062; VG-2062 | Phase 1 Clinical | ViroGin Biotech Ltd, Shanghai Funuojian Biotechnology Co Ltd, Virogin Biotech (Shenzhen) Ltd, Fenojian Biotechnology (Nantong) Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Breast Neoplasms | Details |
FL115 | FL115; FL-115 | Phase 1 Clinical | Suzhou Forlongbiotech Co Ltd | Solid tumours; Urinary Bladder Neoplasms | Details |
QL-415 | QL-415 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Neoplasms | Details |
Recombinant human interleukin 15(Beijing Kawin) | Phase 1 Clinical | Beijing Kawin Technology Share-Holding Co Ltd | Solid tumours | Details | |
PF-07209960 | PF-07209960 | Phase 1 Clinical | Pfizer Inc | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
NKTR-255 | NKTR-255 | Phase 3 Clinical | Nektar Therapeutics | Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Multiple Myeloma; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
SHR-1501 | SHR-1501 | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd | Neoplasms; Urinary Bladder Neoplasms | Details |
XmAb24306 | XmAb-24306; RG-6323; RO-7310729; XmAb-306 | Phase 1 Clinical | Genentech Inc, Xencor Inc | Solid tumours; Neoplasms; Multiple Myeloma | Details |
BJ-001(Boji Biomedical Technology) | BJ-001 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Solid tumours; Communicable Diseases; Neoplasm Metastasis | Details |
ASKG-915 | ASKG-915 | Phase 1 Clinical | Askgene Pharma | Solid tumours; Neoplasms | Details |
ASKG-315 | ASKG-315; ASKG-215b; ASKG-215β | Phase 1 Clinical | Askgene Pharma | Solid tumours; Neoplasms | Details |
VG-201 | VG-201 | Phase 1 Clinical | ViroGin Biotech Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
VG-203 | VG-203; VG2062; VG-2062 | Phase 1 Clinical | ViroGin Biotech Ltd, Shanghai Funuojian Biotechnology Co Ltd, Virogin Biotech (Shenzhen) Ltd, Fenojian Biotechnology (Nantong) Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Breast Neoplasms | Details |
FL115 | FL115; FL-115 | Phase 1 Clinical | Suzhou Forlongbiotech Co Ltd | Solid tumours; Urinary Bladder Neoplasms | Details |
QL-415 | QL-415 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Neoplasms | Details |
Recombinant human interleukin 15(Beijing Kawin) | Phase 1 Clinical | Beijing Kawin Technology Share-Holding Co Ltd | Solid tumours | Details | |
PF-07209960 | PF-07209960 | Phase 1 Clinical | Pfizer Inc | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.